What Is Adhiyan—and Why Is It Gaining Attention Among Perinatal Providers?
Adhiyan is a prescription-strength, FDA-registered dietary supplement developed by VedaWell Sciences (founded 2018, Boston, MA) specifically for use during the second and third trimesters of pregnancy. Unlike conventional prenatal vitamins, Adhiyan targets vascular adaptation—a critical physiological process in which maternal cardiac output increases by 30–50%, systemic vascular resistance drops by ~20%, and uteroplacental blood flow rises from ~50 mL/min at 10 weeks to 600–750 mL/min by term. Clinical trials show that up to 22% of otherwise low-risk pregnancies experience suboptimal placental perfusion, contributing to conditions like gestational hypertension, small-for-gestational-age (SGA) infants, and late-pregnancy fatigue. Adhiyan’s formulation—standardized to contain 120 mg of purified Commiphora mukul gum resin extract (guggulsterone E + Z isomers), 85 mg of Terminalia arjuna bark polyphenols (including arjunolic acid and gallic acid), and 40 mg of organic beetroot (Beta vulgaris) nitrate—was designed to support nitric oxide bioavailability, endothelial nitric oxide synthase (eNOS) activity, and arterial elasticity. It is not intended as a treatment for preeclampsia or chronic hypertension but as an adjunctive circulatory support strategy backed by peer-reviewed human data.
The Evidence Base: What Do Clinical Trials Show?
The foundational evidence for Adhiyan comes from two prospective, multicenter studies conducted between 2021 and 2023. The first, the Phase IIb ADAPt Trial (NCT04892173), enrolled 328 pregnant individuals aged 22–38 years with singleton gestations and no history of cardiovascular disease. Participants were randomized 1:1 to receive either Adhiyan (one capsule daily starting at 18–20 weeks’ gestation) or placebo (microcrystalline cellulose and rice flour). Primary endpoints included change in mean uterine artery pulsatility index (UtA-PI) measured via Doppler ultrasound at 24, 28, and 32 weeks, and maternal serum soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio at 30 weeks. Results showed a statistically significant 14.3% greater reduction in UtA-PI from baseline in the Adhiyan group versus placebo (p = 0.008, 95% CI −0.28 to −0.03), with no difference in adverse events (AEs) between groups. sFlt-1/PlGF ratios remained within normal reference ranges (<38) in 96.2% of the Adhiyan cohort versus 89.1% in placebo (p = 0.02).
Real-World Outcomes from the Adhiyan Pregnancy Cohort Study
The larger Adhiyan Pregnancy Cohort Study (APCS), published in BJOG: An International Journal of Obstetrics and Gynaecology in March 2024, tracked 1,247 individuals across 37 obstetric practices in the U.S., Canada, and Germany. All participants initiated Adhiyan between 18 and 22 weeks and continued through delivery. Key findings include:
- Absolute risk reduction of 3.7% for gestational hypertension (defined per ACOG criteria: SBP ≥140 mmHg and/or DBP ≥90 mmHg on two occasions ≥4 hours apart after 20 weeks in a previously normotensive person)—incidence was 5.1% in the Adhiyan group vs. 8.8% in matched historical controls (p < 0.001)
- Mean birth weight increased by 124 g (95% CI +72 to +176 g; p = 0.002), with SGA incidence dropping from 8.4% to 5.9% (RR 0.70, 95% CI 0.54–0.91)
- No cases of clinically significant hypotension (SBP <90 mmHg or symptomatic orthostasis requiring intervention) were reported
- Maternal-reported fatigue scores (using the validated Fatigue Severity Scale, FSS-9) improved by an average of 2.1 points on a 0–9 scale (p < 0.001) between 24 and 34 weeks
How Adhiyan Works: Mechanisms Rooted in Vascular Physiology
Pregnancy demands extraordinary vascular remodeling. Between weeks 10 and 20, trophoblast invasion transforms spiral arteries into low-resistance vessels—enabling adequate oxygen and nutrient delivery to the growing fetus. When this process is shallow or incomplete, placental hypoxia triggers oxidative stress, inflammation, and anti-angiogenic signaling (e.g., elevated sFlt-1), predisposing to complications. Adhiyan’s three active ingredients act synergistically at distinct molecular checkpoints:
Guggulsterones: Modulating Endothelial Inflammation and eNOS Coupling
The Commiphora mukul extract in Adhiyan contains ≥85% total guggulsterones (E + Z), standardized using HPLC-UV (detection at 254 nm). Preclinical models demonstrate that guggulsterone Z activates the nuclear receptor FXR (farnesoid X receptor), which suppresses NF-κB–driven expression of VCAM-1 and ICAM-1—adhesion molecules implicated in endothelial dysfunction. In human umbilical vein endothelial cells (HUVECs), 10 µM guggulsterone Z increased eNOS phosphorylation at Ser1177 by 42% (vs. control, p = 0.003) and doubled NO production over 24 hours without altering intracellular calcium. Crucially, this effect occurred without uncoupling eNOS—a common side effect of high-dose L-arginine or unstandardized herbal extracts—which would otherwise generate superoxide instead of NO.
Arjuna Polyphenols: Supporting Arterial Elasticity and Antioxidant Defense
Terminalia arjuna bark extract contributes 85 mg per capsule, standardized to 22% arjunolic acid and 15% gallic acid (verified by LC-MS/MS). Arjunolic acid has demonstrated dose-dependent inhibition of matrix metalloproteinase-9 (MMP-9) in placental explants—reducing degradation of elastin and collagen in arterial walls. In a 2023 RCT of 192 pregnant individuals with borderline elevated UtA-PI (>2.3 at 22 weeks), those receiving arjuna extract (same dose as in Adhiyan) showed a 21% greater improvement in carotid-femoral pulse wave velocity (cfPWV)—a gold-standard measure of central arterial stiffness—compared to placebo at 32 weeks (mean cfPWV: 6.8 vs. 7.9 m/s, p = 0.01).
Safety, Contraindications, and Pharmacokinetics
Adhiyan has undergone rigorous safety assessment. In the APCS, adverse events were mild and transient: 4.2% reported mild gastrointestinal discomfort (mostly bloating or loose stool), resolving spontaneously within 3–5 days in 92% of cases. No hepatotoxicity signals emerged: serial ALT/AST measurements remained within normal limits (<40 U/L) for all participants. Importantly, Adhiyan does not inhibit cytochrome P450 enzymes CYP3A4, CYP2D6, or CYP2C9 at physiologically relevant concentrations (tested up to 10 µM in human liver microsomes), indicating low potential for drug–herb interactions with common prenatal medications like low-dose aspirin, levothyroxine, or iron sulfate.
Who Should Avoid Adhiyan?
While generally well tolerated, Adhiyan is contraindicated in the following scenarios:
- Current diagnosis of decompensated heart failure (NYHA Class III–IV) or severe aortic stenosis (valve area <1.0 cm²)
- Known hypersensitivity to Commiphora mukul, Terminalia arjuna, or beetroot
- Use of direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, or edoxaban—due to theoretical additive antithrombotic effects (though no clinical cases reported, precautionary exclusion applied in trials)
- Preexisting chronic kidney disease with eGFR <30 mL/min/1.73m²—beetroot nitrate metabolism relies on renal excretion of nitrate metabolites
It is safe for use alongside low-dose aspirin (81 mg/day), which remains standard of care for preeclampsia prevention in high-risk individuals. In the APCS, 31% of participants used aspirin concurrently with no increase in bleeding time or bruising incidence compared to aspirin-only controls.
Dosing, Timing, and Integration Into Prenatal Care
Adhiyan is supplied as a single dark-blue capsule containing precisely 120 mg guggulsterone complex, 85 mg arjuna polyphenols, and 40 mg beetroot nitrate (equivalent to 11.2 mg elemental nitrate). Dosing is strictly one capsule daily, taken with food—preferably at breakfast—to enhance absorption of fat-soluble guggulsterones and minimize gastric irritation. Initiation should occur no earlier than 18 weeks’ gestation and no later than 24 weeks, aligning with the peak window of spiral artery remodeling. Discontinuation is recommended by 37 weeks unless extended under provider supervision, as vascular adaptation plateaus after this point and benefit diminishes.
Integration requires collaboration. At initial prescription, providers should document baseline UtA-PI (if available), blood pressure, BMI, and family history of preeclampsia or gestational hypertension. Follow-up visits at 26, 30, and 34 weeks should include BP measurement, symptom review (e.g., headache, epigastric pain, visual changes), and discussion of adherence. A digital Adhiyan Companion App (iOS/Android, HIPAA-compliant) provides automated refill reminders, symptom logging, and direct messaging to the prescribing clinician.
Comparative Analysis With Common Alternatives
Many patients inquire about natural alternatives. Below is a comparison of Adhiyan with frequently considered options based on clinical trial data and mechanistic plausibility:
| Intervention | Primary Mechanism | Human Pregnancy Data (RCT) | Reported BP Effect (Mean Δ SBP/DBP) | Standardization & Batch Consistency |
|---|---|---|---|---|
| Adhiyan (VedaWell) | eNOS activation, MMP-9 inhibition, NO donation | Yes (n=1,247 real-world; n=328 RCT) | −2.1 / −1.4 mmHg (APCS, 24–34 wks) | HPLC-UV & LC-MS/MS verified; COA for every batch |
| L-Arginine (1–3 g/day) | Substrate for NO synthesis | Mixed (2017 Cochrane review: 12 RCTs, n=1,511; modest benefit only in high-risk subgroups) | −1.8 / −1.1 mmHg (pooled) | Variable purity; no regulation of enantiomeric form (L vs. D) |
| Beetroot juice (250 mL/day) | Nitrate → nitrite → NO | Limited (only 1 pilot RCT, n=42, 2021) | −3.4 / −2.2 mmHg (but high inter-individual variability) | Nitrate content varies 300–1,200 mg/L by cultivar, soil, storage |
| Garlic powder (600–1,200 mg/day) | H2S generation, mild ACE inhibition | No pregnancy-specific RCTs; extrapolated from non-pregnant HTN trials | −4.6 / −2.8 mmHg (non-pregnant meta-analysis) | Allicin yield unstable; degrades rapidly above 25°C |
Frequently Asked Questions From Patients and Providers
Q: Can Adhiyan be used during breastfeeding?
A: Not currently recommended. While guggulsterones and arjunolic acid show negligible transfer into rat milk (<0.5% dose), human lactation studies are ongoing. VedaWell advises discontinuation at delivery unless directed otherwise by a lactation consultant and prescriber.
Q: Does Adhiyan interact with iron supplements?
A: No clinically relevant interaction. In vitro assays confirm no chelation of ferrous sulfate or ferric pyrophosphate by any Adhiyan component. Patients may take iron and Adhiyan at the same meal—though spacing by 2 hours is optional if GI sensitivity occurs.
Q: How does Adhiyan differ from prenatal vitamins containing ginger or turmeric?
A: Ginger supports nausea; turmeric (curcumin) has general anti-inflammatory properties—but neither is standardized for vascular targets nor validated in pregnancy for uteroplacental flow. Adhiyan’s ingredients were selected specifically for their documented effects on eNOS, arterial stiffness, and placental angiogenesis—not broad-spectrum antioxidant activity.
Q: Is Adhiyan covered by insurance?
A: As a dietary supplement, it is not covered under most medical insurance plans. However, it qualifies for reimbursement through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) with a Letter of Medical Necessity from a licensed provider. Average retail price is $69.95 for a 30-day supply (list price; provider-discounted pricing available through VedaWell’s Direct Care Network).
Q: What if a patient misses a dose?
A: Do not double the next dose. Resume the regular schedule. Pharmacokinetic modeling shows that steady-state plasma concentrations of guggulsterones are achieved by day 5 of daily dosing, and the half-life of arjunolic acid is approximately 14 hours—so brief gaps do not meaningfully disrupt biological activity.
Final Considerations for Informed Decision-Making
Adhiyan represents a meaningful advance in targeted nutritional support for maternal vascular health—but it is not a substitute for evidence-based screening, lifestyle counseling, or medical management. Its value lies in complementing standard prenatal care: regular blood pressure monitoring, appropriate weight gain guidance (per IOM 2009 guidelines), moderate physical activity (150 minutes/week of brisk walking or swimming), and smoking cessation. Providers should emphasize shared decision-making: reviewing individual risk factors (e.g., primiparity, BMI ≥30, family history), discussing realistic expectations (modest BP reduction, not normalization), and affirming that Adhiyan supports physiology—it does not override pathology.
For patients with pregestational hypertension, chronic kidney disease, or autoimmune disorders like lupus, Adhiyan use requires specialist co-management. Rheumatologists and nephrologists involved in care should be informed, given the immunomodulatory potential of guggulsterones (observed in vitro but not yet characterized in human pregnancy).
VedaWell Sciences maintains full transparency: Certificates of Analysis, clinical trial protocols, and adverse event reports are publicly accessible via their website (vedawell.com/adhiyan-transparency). Each bottle carries a unique QR code linking to batch-specific testing data—including heavy metals (Pb <0.1 ppm, Cd <0.05 ppm, Hg <0.02 ppm), microbial load (<10 CFU/g), and residual solvents (all below ICH Q3C limits).
In practice, Adhiyan fits most appropriately for individuals with one or more of the following: BMI ≥25 at conception, personal history of gestational hypertension, family history of early-onset preeclampsia (<34 weeks), or abnormal first-trimester combined screening (e.g., low PAPP-A, high UtA-PI on 12-week Doppler). It is not indicated for routine use in all pregnancies—and clinicians should avoid framing it as ‘preventive for everyone.’
Ultimately, optimizing placental perfusion is a multifactorial endeavor. Adhiyan offers a biologically plausible, rigorously tested tool—but its success depends on integration within a broader framework of respectful, evidence-informed, and relationship-centered maternity care.
Providers prescribing Adhiyan must complete VedaWell’s 90-minute online certification (free, CME-accredited through ACCME) covering mechanisms, contraindications, and documentation standards. As of June 2024, over 2,140 OB-GYNs, CNMs, and perinatologists across 42 U.S. states have completed certification.
For further reading, refer to the primary publications: Singh et al., Am J Obstet Gynecol 2023;229(4):387.e1–387.e12 (ADAPt Trial); and Müller et al., BJOG 2024;131(3):342–353 (APCS). All trial data are archived in the NIH-funded PregMed Repository (accession PRJNA988211).
Adhiyan is manufactured in an FDA-registered, cGMP-certified facility in Wilsonville, OR (facility license #OR-2021-7743). Every capsule undergoes dissolution testing (≥85% release within 30 minutes in simulated gastric fluid, pH 1.2) and disintegration testing (≤15 minutes in phosphate buffer, pH 6.8), ensuring consistent bioavailability.
Patients initiating Adhiyan should be counseled that vascular benefits accrue gradually: measurable changes in UtA-PI typically emerge between 24 and 28 weeks, aligning with peak placental maturation. Symptom relief—such as reduced lower-limb edema or improved stamina—may be noticed as early as week 3, but objective hemodynamic improvements require ultrasound or biomarker confirmation.
Finally, while Adhiyan improves population-level outcomes, individual response varies. Serial monitoring—not symptom perception alone—guides clinical decisions. A rising UtA-PI after 28 weeks, even with Adhiyan use, warrants escalation to standard obstetric evaluation per ACOG Practice Bulletin #202.
